Three year results of the prostatic urethral L.I.F.T. study

Claus Roehrborn, Daniel B. Rukstalis, Jack Barkin, Steven N. Gange, Neal D. Shore, Jonathan L. Giddens, Damien M. Bolton, Barrett E. Cowan, Anthony L. Cantwell, Kevin T. McVary, Alexis E. Te, Shahram S. Gholami, William G. Moseley, Peter T. Chin, William T. Dowling, Sheldon J. Freedman, Peter F. Incze, K. Scott Coffield, Fernando D. Borges, Prem Rashid

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Introduction: To report the three year results of a multicenter, randomized, patient and outcome assessor blinded trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS) ≥ 13, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume between 30 cc-80 cc were randomized 2:1 to the PUL procedure or sham control. PUL involved placing permanent UroLift implants into the lateral lobes of the prostate to enlarge the urethral lumen. After randomized comparison at 3 months, PUL patients were followed to 3 years. LUTS severity (IPSS), quality of life, Qmax, sexual function, and adverse events were assessed throughout follow up. Results: The therapeutic effect of PUL regarding IPSS was 88% greater than sham at 3 months. Average improvements from baseline through 3 years were significant for total IPSS (41.1%), quality of life (48.8%), Qmax (53.1%), and individual IPSS symptoms. Symptomatic improvement was independent of prostate size. There were no de novo, sustained ejaculatory or erectile dysfunction events and all sexual function assessments showed average stability or improvement after PUL. Fifteen of the 140 patients originally randomized to PUL required surgical reintervention for treatment failure within the first 3 years. Conclusions: PUL offers rapid improvement in voiding and storage symptoms, quality of life and flow rate that is durable to 3 years. Patients demonstrated a level of symptom relief that is associated with significant patient satisfaction. PUL, a minimally invasive procedure, is very effective in treating bothersome LUTS secondary to benign prostatic obstruction (BPO) and is unique in its ability to preserve total sexual function while offering a rapid return to normal physical activities.

Original languageEnglish (US)
Pages (from-to)7772-7782
Number of pages11
JournalCanadian Journal of Urology
Volume22
Issue number3
StatePublished - 2015

Fingerprint

Prostate
Lower Urinary Tract Symptoms
Quality of Life
Aptitude
Prostatic Hyperplasia
Therapeutic Uses
Erectile Dysfunction
North America
Treatment Failure
Patient Satisfaction
Exercise

Keywords

  • BPH
  • Minimally invasive
  • Sexual function
  • Surgery
  • Surgical therapy

ASJC Scopus subject areas

  • Urology

Cite this

Roehrborn, C., Rukstalis, D. B., Barkin, J., Gange, S. N., Shore, N. D., Giddens, J. L., ... Rashid, P. (2015). Three year results of the prostatic urethral L.I.F.T. study. Canadian Journal of Urology, 22(3), 7772-7782.

Three year results of the prostatic urethral L.I.F.T. study. / Roehrborn, Claus; Rukstalis, Daniel B.; Barkin, Jack; Gange, Steven N.; Shore, Neal D.; Giddens, Jonathan L.; Bolton, Damien M.; Cowan, Barrett E.; Cantwell, Anthony L.; McVary, Kevin T.; Te, Alexis E.; Gholami, Shahram S.; Moseley, William G.; Chin, Peter T.; Dowling, William T.; Freedman, Sheldon J.; Incze, Peter F.; Coffield, K. Scott; Borges, Fernando D.; Rashid, Prem.

In: Canadian Journal of Urology, Vol. 22, No. 3, 2015, p. 7772-7782.

Research output: Contribution to journalArticle

Roehrborn, C, Rukstalis, DB, Barkin, J, Gange, SN, Shore, ND, Giddens, JL, Bolton, DM, Cowan, BE, Cantwell, AL, McVary, KT, Te, AE, Gholami, SS, Moseley, WG, Chin, PT, Dowling, WT, Freedman, SJ, Incze, PF, Coffield, KS, Borges, FD & Rashid, P 2015, 'Three year results of the prostatic urethral L.I.F.T. study', Canadian Journal of Urology, vol. 22, no. 3, pp. 7772-7782.
Roehrborn C, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL et al. Three year results of the prostatic urethral L.I.F.T. study. Canadian Journal of Urology. 2015;22(3):7772-7782.
Roehrborn, Claus ; Rukstalis, Daniel B. ; Barkin, Jack ; Gange, Steven N. ; Shore, Neal D. ; Giddens, Jonathan L. ; Bolton, Damien M. ; Cowan, Barrett E. ; Cantwell, Anthony L. ; McVary, Kevin T. ; Te, Alexis E. ; Gholami, Shahram S. ; Moseley, William G. ; Chin, Peter T. ; Dowling, William T. ; Freedman, Sheldon J. ; Incze, Peter F. ; Coffield, K. Scott ; Borges, Fernando D. ; Rashid, Prem. / Three year results of the prostatic urethral L.I.F.T. study. In: Canadian Journal of Urology. 2015 ; Vol. 22, No. 3. pp. 7772-7782.
@article{133cd8e587244a03aa42a47b8118e8ab,
title = "Three year results of the prostatic urethral L.I.F.T. study",
abstract = "Introduction: To report the three year results of a multicenter, randomized, patient and outcome assessor blinded trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS) ≥ 13, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume between 30 cc-80 cc were randomized 2:1 to the PUL procedure or sham control. PUL involved placing permanent UroLift implants into the lateral lobes of the prostate to enlarge the urethral lumen. After randomized comparison at 3 months, PUL patients were followed to 3 years. LUTS severity (IPSS), quality of life, Qmax, sexual function, and adverse events were assessed throughout follow up. Results: The therapeutic effect of PUL regarding IPSS was 88{\%} greater than sham at 3 months. Average improvements from baseline through 3 years were significant for total IPSS (41.1{\%}), quality of life (48.8{\%}), Qmax (53.1{\%}), and individual IPSS symptoms. Symptomatic improvement was independent of prostate size. There were no de novo, sustained ejaculatory or erectile dysfunction events and all sexual function assessments showed average stability or improvement after PUL. Fifteen of the 140 patients originally randomized to PUL required surgical reintervention for treatment failure within the first 3 years. Conclusions: PUL offers rapid improvement in voiding and storage symptoms, quality of life and flow rate that is durable to 3 years. Patients demonstrated a level of symptom relief that is associated with significant patient satisfaction. PUL, a minimally invasive procedure, is very effective in treating bothersome LUTS secondary to benign prostatic obstruction (BPO) and is unique in its ability to preserve total sexual function while offering a rapid return to normal physical activities.",
keywords = "BPH, Minimally invasive, Sexual function, Surgery, Surgical therapy",
author = "Claus Roehrborn and Rukstalis, {Daniel B.} and Jack Barkin and Gange, {Steven N.} and Shore, {Neal D.} and Giddens, {Jonathan L.} and Bolton, {Damien M.} and Cowan, {Barrett E.} and Cantwell, {Anthony L.} and McVary, {Kevin T.} and Te, {Alexis E.} and Gholami, {Shahram S.} and Moseley, {William G.} and Chin, {Peter T.} and Dowling, {William T.} and Freedman, {Sheldon J.} and Incze, {Peter F.} and Coffield, {K. Scott} and Borges, {Fernando D.} and Prem Rashid",
year = "2015",
language = "English (US)",
volume = "22",
pages = "7772--7782",
journal = "The Canadian journal of urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "3",

}

TY - JOUR

T1 - Three year results of the prostatic urethral L.I.F.T. study

AU - Roehrborn, Claus

AU - Rukstalis, Daniel B.

AU - Barkin, Jack

AU - Gange, Steven N.

AU - Shore, Neal D.

AU - Giddens, Jonathan L.

AU - Bolton, Damien M.

AU - Cowan, Barrett E.

AU - Cantwell, Anthony L.

AU - McVary, Kevin T.

AU - Te, Alexis E.

AU - Gholami, Shahram S.

AU - Moseley, William G.

AU - Chin, Peter T.

AU - Dowling, William T.

AU - Freedman, Sheldon J.

AU - Incze, Peter F.

AU - Coffield, K. Scott

AU - Borges, Fernando D.

AU - Rashid, Prem

PY - 2015

Y1 - 2015

N2 - Introduction: To report the three year results of a multicenter, randomized, patient and outcome assessor blinded trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS) ≥ 13, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume between 30 cc-80 cc were randomized 2:1 to the PUL procedure or sham control. PUL involved placing permanent UroLift implants into the lateral lobes of the prostate to enlarge the urethral lumen. After randomized comparison at 3 months, PUL patients were followed to 3 years. LUTS severity (IPSS), quality of life, Qmax, sexual function, and adverse events were assessed throughout follow up. Results: The therapeutic effect of PUL regarding IPSS was 88% greater than sham at 3 months. Average improvements from baseline through 3 years were significant for total IPSS (41.1%), quality of life (48.8%), Qmax (53.1%), and individual IPSS symptoms. Symptomatic improvement was independent of prostate size. There were no de novo, sustained ejaculatory or erectile dysfunction events and all sexual function assessments showed average stability or improvement after PUL. Fifteen of the 140 patients originally randomized to PUL required surgical reintervention for treatment failure within the first 3 years. Conclusions: PUL offers rapid improvement in voiding and storage symptoms, quality of life and flow rate that is durable to 3 years. Patients demonstrated a level of symptom relief that is associated with significant patient satisfaction. PUL, a minimally invasive procedure, is very effective in treating bothersome LUTS secondary to benign prostatic obstruction (BPO) and is unique in its ability to preserve total sexual function while offering a rapid return to normal physical activities.

AB - Introduction: To report the three year results of a multicenter, randomized, patient and outcome assessor blinded trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS) ≥ 13, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume between 30 cc-80 cc were randomized 2:1 to the PUL procedure or sham control. PUL involved placing permanent UroLift implants into the lateral lobes of the prostate to enlarge the urethral lumen. After randomized comparison at 3 months, PUL patients were followed to 3 years. LUTS severity (IPSS), quality of life, Qmax, sexual function, and adverse events were assessed throughout follow up. Results: The therapeutic effect of PUL regarding IPSS was 88% greater than sham at 3 months. Average improvements from baseline through 3 years were significant for total IPSS (41.1%), quality of life (48.8%), Qmax (53.1%), and individual IPSS symptoms. Symptomatic improvement was independent of prostate size. There were no de novo, sustained ejaculatory or erectile dysfunction events and all sexual function assessments showed average stability or improvement after PUL. Fifteen of the 140 patients originally randomized to PUL required surgical reintervention for treatment failure within the first 3 years. Conclusions: PUL offers rapid improvement in voiding and storage symptoms, quality of life and flow rate that is durable to 3 years. Patients demonstrated a level of symptom relief that is associated with significant patient satisfaction. PUL, a minimally invasive procedure, is very effective in treating bothersome LUTS secondary to benign prostatic obstruction (BPO) and is unique in its ability to preserve total sexual function while offering a rapid return to normal physical activities.

KW - BPH

KW - Minimally invasive

KW - Sexual function

KW - Surgery

KW - Surgical therapy

UR - http://www.scopus.com/inward/record.url?scp=84932131194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932131194&partnerID=8YFLogxK

M3 - Article

C2 - 26068624

AN - SCOPUS:84932131194

VL - 22

SP - 7772

EP - 7782

JO - The Canadian journal of urology

JF - The Canadian journal of urology

SN - 1195-9479

IS - 3

ER -